Risk of developing malignant peripheral nerve sheath tumors in patients with neurofibromatosis 1 receiving MEK inhibitor treatment for plexiform neurofibromas
Clicks: 1
ID: 323075
2026
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
0.0
/100
1 views
0 readers
AI Quality Assessment
Not analyzed
Readership in this journal
Ranked #81 of 103 articles by views in Neuro-Oncology Advances
Most read
Least read
Bar heights use a square-root scale.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Abstract Background Mitogen activating protein kinase kinase inhibitors (MEKi) provide clinical benefit to patients with symptomatic, inoperable plexiform neurofibromas (PNs) in Neurofibromatosis type 1 (NF1). Several cases of MPNST developing in patients while receiving MEKi for PN have been reported, raising the question whether MEKi therapy might increase this risk. We report the incidence of MPNST in those who have received MEKi, non-MEKi (e.g. mTOR inhibitors), and no PN-directed medical therapies and assess the risk of MPNST in patients who received MEKi. Methods Patients evaluated at the National Cancer Institute (NCI) with a clinical or genetic diagnosis of NF1 from 1/1/1998-12/31/2019 were included in this analysis (n = 296). Patients were categorized as MEKi (n = 29), non-MEKi (n = 91), both (n = 45), or no medical treatment (n = 131); only patients who received PN-directed medical treatment were included in the analysis of MPNST risk. Univariate evaluations of risk factors associated with MPNST were included in a multivariate model with treatment group as a time-dependent covariate. Results No difference in MPNST risk (HR:1.09, 95%CI: 0.30-4.01) between MEKi as compared to non-MEKi treatment was observed after adjusting for radiation exposure. Radiation exposure was associated with a higher risk of MPNST (HR 5.15, 95%CI: 1.15-23.04). Other patient characteristics, including NF1 inheritance pattern, were not associated with the risk of MPNST development in this cohort. Conclusion Our data does not demonstrate a significant difference in the risk of MPNST development between patients with NF1-PN who received MEKi and non-MEKi treatments. Radiation exposure was significantly associated with a higher risk of MPNST development.
| Reference Key |
openalex_W7172011697
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Hari Sankaran, Eva Dombi, Brittany Glassberg, Andrea Baldwin, Kara Heisey, Anne Dufek, Cecilia Tibery, Ana F. Best, Alice Chen, Brigitte C. Widemann, Andrea M. Gross |
| Journal | Neuro-Oncology Advances |
| Year | 2026 |
| DOI |
10.1093/noajnl/vdag201
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.